Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Appleby

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Thrombosis and Haemostasis|October 1, 1995
Inhibition of thrombin by peptides containing Lysyl-alpha-keto carbonyl derivativesS D Lewis, A S Ng, E A Lyle, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]J J Lynch, A A Wallace, R F Stupienski, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agentJ J Lynch, A A Wallace, L H Van der Gaag, et al.
Journal of Medicinal Chemistry|May 23, 1997
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacyT J Tucker, W C Lumma, S D Lewis, et al.
Translational Psychiatry|April 11, 2013
Alterations in metabolic pathways and networks in Alzheimer's diseaseR Kaddurah-Daouk, H Zhu, S Sharma, et al.
HIV Medicine|December 31, 2025
Supporting long-term engagement in HIV clinical care: Learning from the COVID-19 pandemicR Dhairyawan, Sara Paparini, M Smuk, et al.
Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.
Journal of Medicinal Chemistry|February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid supportS F Brady, K J Stauffer, W C Lumma, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Thrombosis and Haemostasis|October 1, 1995
Inhibition of thrombin by peptides containing Lysyl-alpha-keto carbonyl derivativesS D Lewis, A S Ng, E A Lyle, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1994
Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]J J Lynch, A A Wallace, R F Stupienski, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1993
Cardiac electrophysiologic and antiarrhythmic actions of 3,4-dihydro-1'-[2-(benzofurazan-5-yl) ethyl]-6-methanesulfonamidospiro [(2H)-1-benzopyran-2,4'-piperidin]-4-one HCl (L-691,121), a novel class III agentJ J Lynch, A A Wallace, L H Van der Gaag, et al.
Journal of Medicinal Chemistry|May 23, 1997
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacyT J Tucker, W C Lumma, S D Lewis, et al.
Translational Psychiatry|April 11, 2013
Alterations in metabolic pathways and networks in Alzheimer's diseaseR Kaddurah-Daouk, H Zhu, S Sharma, et al.
HIV Medicine|December 31, 2025
Supporting long-term engagement in HIV clinical care: Learning from the COVID-19 pandemicR Dhairyawan, Sara Paparini, M Smuk, et al.
Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.
Journal of Medicinal Chemistry|February 17, 1998
Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460): coapplication of structure-based design and rapid multiple analogue synthesis on solid supportS F Brady, K J Stauffer, W C Lumma, et al.
Pageof 3